Plasma neurofilament light levels are associated with the risk of disability in multiple sclerosis


  • Elevated plasma neurofilament light chain (pNfL) levels may be used as a prognostic marker and treatment monitoring tool for assessment of risk of permanent disability in patients with multiple sclerosis (MS).

Why this matters

  • It is often difficult to forecast the long-term prognosis in patients with MS due to the highly variable interpatient disease course.

  • Prognostic biomarkers can aid treatment decisions, particularly at the early stages of the disease.